Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial (ClinicalTrials.gov – NCT04243863) of VNRX-7145, a novel component of the investigational oral antibiotic combination product. VNRX-7145, in combination with ceftibuten, a third-generation, orally-bioavailable cephalosporin antibiotic, is designed for the treatment of patients with infections caused by multi-drug resistant (MDR) gram-negative pathogens that are resistant to current standard-of-care oral and intravenous antibiotics, including fluoroquinolones, cephalosporins and carbapenems.
Venatorx Pharmaceuticals was named one of the “2021 Best Places to Work” in the medium-sized company category in the Greater Philadelphia area by the Philadelphia Business Journal. This year marks Venatorx’s 11th Anniversary. Being named a ‘Best Places to Work’ for the fourth year in a row comes at a fitting time to acknowledge our team’s unwavering commitment to bring lifesaving antibiotics and antiviral medicines to patients around the globe.
With over 30 years’ experience in the pharmaceuticals industry, Dr. Dorr will be responsible for planning and executing clinical development across Venatorx’s anti-infectives portfolio including its two antibacterial programs, cefepime-taniborbactam and ceftibuten/VNRX-7145, as well as its antiviral program, VNRX-9945, a Hepatitis B virus inhibitor.
The Phase 1 clinical trial will evaluate the safety and pharmacokinetics of single and multiple ascending doses of VNRX-9945, administered orally in healthy adult volunteers (ClinicalTrials.gov – NCT04845321).
Venatorx Pharmaceuticals will present the "Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of hepatitis B virus (HBV) infection" at the International Liver CongressTM (ILC), the European Association for the Study of the Liver (EASL) annual meeting, which is scheduled to take place virtually June 23-26, 2021.
Venatorx Pharmaceuticals selected VNRX-9945, a core protein allosteric modulator (CpAM), as a clinical candidate for the treatment of chronic Hepatitis B Virus (HBV) infection. The Company plans to initiate clinical development in the second quarter 2021.
With nearly 25 years’ experience in pharmaceutical research, regulatory affairs and compliance, Dr. Abey will be responsible for developing and executing all regulatory strategies and tactics for Venatorx’s antibacterial and antiviral programs including interacting with health authorities and managing clinical trial applications worldwide.
With over 30 years of experience in CMC development and commercialization, Dr. Waltermire will be responsible for all CMC across Venatorx’s portfolio including drug substance and drug product activities from preclinical development through clinical supplies for Phase 3 registration studies and eventual transition to commercial supply.